Literature DB >> 24861474

The effect of oral contraceptive different patterns of use on circulating IGF-1 and bone mineral density in healthy premenopausal women.

Amany Y Elkazaz1, Khaled Salama.   

Abstract

Both insulin-like growth factor-1(IGF-1) and oral contraceptive (OC) use have been linked to premenopausal breast and colorectal cancers, osteoporosis and cardiovascular disease. Understanding the effects of different patterns of use of OC on IGF-1 levels and bone mineral density (BMD) may offer insight into its influence on osteoporosis. We conducted a cross-sectional study, which included 135 women, who were then divided into three groups: Group A who were OC current users, 41 women; Group B who never use OC, 51 women; and Group C who were past users of OC, 41 women. Each patient completed a questionnaire on demographic parameters, marital state history and contraception history including duration of use and type of contraceptive pills or used method. Lower-end radius, proximal femur and lumbar spine BMD were measured by dual-energy X-ray absorptiometry. IGF-1 was assessed with chemiluminescent immunometric assay. The three groups were similar in total body T value of BMD (with slight better results in past users than the other two groups but it was statistically insignificant difference), and past users showed significantly higher BMD values compared to current users at spine, femur and forearm. Nonusers also had better BMD values compared to current users (spine and forearm BMD). Among past users, the mean level of circulating IGF-1 was higher than the other two groups and that difference was statistically significant. Past OC use and/or nonuse has a more favorable impact on BMD compared to current use and that this relationship is in part mediated by IGF-1. Hence, it appears that OC use is beneficial to BMD if used in the past and then discontinued or if never used at all compared to current use.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24861474     DOI: 10.1007/s12020-014-0290-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  34 in total

Review 1.  Low-dose oral contraceptives and bone mineral density: an evidence-based analysis.

Authors:  W Kuohung; L Borgatta; P Stubblefield
Journal:  Contraception       Date:  2000-02       Impact factor: 3.375

2.  Effect of combined oral contraceptives on bone mineral density in pre and postmenopausal women.

Authors:  Sayeeda Sultana; Shahnaz Choudhury; S A R Choudhury
Journal:  Mymensingh Med J       Date:  2002-01

Review 3.  Insulin-like growth factor binding proteins.

Authors:  M M Rechler
Journal:  Vitam Horm       Date:  1993       Impact factor: 3.421

4.  Bone mineral density measured by dual-energy X-ray absorptiometry in healthy Finnish women.

Authors:  K Laitinen; M Välimäki; P Keto
Journal:  Calcif Tissue Int       Date:  1991-04       Impact factor: 4.333

5.  Oral-contraceptive use and risk of hip fracture: a case-control study.

Authors:  K Michaëlsson; J A Baron; B Y Farahmand; I Persson; S Ljunghall
Journal:  Lancet       Date:  1999-05-01       Impact factor: 79.321

6.  Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH).

Authors:  A Balogh; E Kauf; R Vollanth; G Gräser; G Klinger; M Oettel
Journal:  Contraception       Date:  2000-11       Impact factor: 3.375

7.  Bone mineral density at various anatomic bone sites in women receiving combined oral contraceptives and depot-medroxyprogesterone acetate for contraception.

Authors:  P Wanichsetakul; A Kamudhamas; P Watanaruangkovit; Y Siripakarn; P Visutakul
Journal:  Contraception       Date:  2002-06       Impact factor: 3.375

8.  Oral contraceptive use may protect against low bone mass. Henry Ford Hospital Osteoporosis Cooperative Research Group.

Authors:  M Kleerekoper; R S Brienza; L R Schultz; C C Johnson
Journal:  Arch Intern Med       Date:  1991-10

9.  Body shape throughout life and correlations with IGFs and GH.

Authors:  Eva S Schernhammer; Shelley S Tworoger; A Heather Eliassen; Stacey A Missmer; Jeff M Holly; Michael N Pollak; Susan E Hankinson
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

Review 10.  The IGF-I signaling pathway.

Authors:  Luigi Laviola; Annalisa Natalicchio; Francesco Giorgino
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more
  5 in total

1.  Oral contraceptive use, bone mineral density, and bone turnover markers over 12 months in college-aged females.

Authors:  Hawley C Almstedt; Makenzie M Cook; Lily F Bramble; Deepa V Dabir; Joseph W LaBrie
Journal:  J Bone Miner Metab       Date:  2020-01-25       Impact factor: 2.626

2.  Reference Values for IGF-I Serum Concentrations: Comparison of Six Immunoassays.

Authors:  Philippe Chanson; Armelle Arnoux; Maria Mavromati; Sylvie Brailly-Tabard; Catherine Massart; Jacques Young; Marie-Liesse Piketty; Jean-Claude Souberbielle
Journal:  J Clin Endocrinol Metab       Date:  2016-05-11       Impact factor: 5.958

3.  Are the Effects of Oral and Vaginal Contraceptives on Bone Formation in Young Women Mediated via the Growth Hormone-IGF-I Axis?

Authors:  Heather C M Allaway; Madhusmita Misra; Emily A Southmayd; Michael S Stone; Connie M Weaver; Dylan L Petkus; Mary Jane De Souza
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-16       Impact factor: 5.555

4.  Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS.

Authors:  Aesha Shah; William C Dodson; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Carol L Gnatuk; Stephanie J Estes; Kelly C Allison; David B Sarwer; Patrick M Sluss; Christos Coutifaris; Anuja Dokras; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

5.  Reference ranges for serum insulin-like growth factor I (IGF-I) in healthy Chinese adults.

Authors:  Huijuan Zhu; Yuan Xu; Fengying Gong; Guangliang Shan; Hongbo Yang; Ke Xu; Dianxi Zhang; Xinqi Cheng; Zhihao Zhang; Shi Chen; Linjie Wang; Hui Pan
Journal:  PLoS One       Date:  2017-10-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.